Semaglutide News and Research

Latest Semaglutide News and Research

An Arm and a Leg: Wait, is Insulin cheaper now?

Pharmaceutical companies that manufacture insulin made headlines last year when they voluntarily agreed to provide discount cards that lower the monthly cost of insulin for many people to $35.

28 Feb 2024

Bariatric surgery outperforms medical management in long-term diabetes control

People with type 2 diabetes who underwent bariatric surgery achieved much better long-term blood glucose control compared to people who received medical management plus lifestyle interventions, according to a new study published in JAMA, or Journal of the American Medical Association, and funded by the National institute of Diabetes, Digestive and Kidney Diseases, part of The National Institutes of Health.

27 Feb 2024

Underutilized obesity treatments could transform patient health

When someone has obesity, losing even 5% of their body weight can make a major difference in their health -- especially if they can keep from regaining it.

21 Feb 2024

Lactocore Group leverages milk peptides to combat inflammaging

...

From Lactocore Group 21 Feb 2024

AMG 133 (maridebart cafraglutide) weight loss drug shows promise in early trial

AMG 133, an engineered bispecific molecule, demonstrated significant weight loss with a favorable safety profile in a phase 1 clinical trial, offering a promising new treatment option for obesity.

7 Feb 2024

New weight loss drug may be an effective strategy for preventing or treating high blood pressure

The new weight loss medication tirzepatide significantly lowered the systolic blood pressure (the top number in a blood pressure reading) for nearly 500 adults with obesity who took the medication for about eight months, according to new research published today in Hypertension, an American Heart Association journal.

5 Feb 2024

Over 80% of semaglutide users achieve significant weight loss after 12 months, study finds

...

5 Feb 2024

What does the future hold for obesity medication development?

The safety, clinical implications, and challenges of obesity pharmacotherapies based on entero-pancreatic hormone- treatments.

5 Feb 2024

Breakthrough obesity treatments on the horizon, rivaling surgery's success

New obesity pharmacotherapies, including GLP-1 receptor agonists and combinations of entero-pancreatic hormones, show promise in achieving significant weight loss, potentially rivaling bariatric surgery's effectiveness.

4 Feb 2024

SGLT2 inhibitors linked to lower risk of kidney stones in patients with type 2 diabetes

Rates of kidney stones are on the rise in the United States and around the world. Type 2 diabetes is associated with increased risk of kidney stones, but some forms of treatment for this condition may also have the benefit of lowering risk of kidney stones.

31 Jan 2024

Fermented foods linked to mental health benefits through gut-brain connection

Researchers explore the mental health benefits of fermented foods on the microbiota-gut-brain axis, highlighting the need for further studies to understand their therapeutic potential.

29 Jan 2024

Study links GLP1 agonists to reduced risk of severe liver disease in diabetic patients

Ozempic and other GLP1 agonists are associated with a reduced risk of developing cirrhosis and liver cancer in people with type 2 diabetes and chronic liver disease, according to a nationwide study from Karolinska Institutet in Sweden published in the journal Gut.

23 Jan 2024

Dietary factors influencing GLP-1 secretion: a new perspective in diabetes and obesity treatment

Researchers in The American Journal of Clinical Nutrition review the impact of diet on GLP-1 secretion in metabolic conditions like obesity and type 2 diabetes, highlighting its potential in treatment and prevention.

16 Jan 2024

Diabetes drugs may help curb alcohol dependence

In social media posts on the community network Reddit, users reported reduced cravings for alcohol when taking drugs intended to treat Type 2 diabetes and obesity.

8 Jan 2024

GLP-1R agonist liraglutide rapidly improves insulin sensitivity in pre-diabetics, independent of weight loss

A new study published in the journal Diabetes demonstrates that a glucagon-like peptide-1 receptor (GLP-1R) agonist, a member of a class of medication used to treat Type 2 diabetes and obesity, can lead to a rapid improvement in insulin sensitivity.

4 Jan 2024

Combination therapy of dapagliflozin and semaglutide shows superior efficacy in type 2 diabetes management

Study demonstrates that combining dapagliflozin and semaglutide significantly improves glycemic control and other health parameters in type 2 diabetes patients, outperforming dapagliflozin alone.

3 Jan 2024

MIT engineers develop 'vibing belly' pill to control appetite and curb obesity

When you eat a large meal, your stomach sends signals to your brain that create a feeling of fullness, which helps you realize it's time to stop eating.

26 Dec 2023

MHRA provides 5 festive top tips for people taking medicines or using medical devices

Christmas and New Year is a time when we particularly want to keep well and stay safe. The Medicines and Healthcare products Regulatory Agency (MHRA) has set out 5 festive top tips for people taking medicines or using medical devices.

21 Dec 2023

Diabetes drug may help women avoid weight gain after quitting smoking

The diabetes drug dulaglutide (Trulicity) may significantly lower a woman's risk of substantial weight gain after she has given up smoking, finds a secondary analysis of clinical trial data, published in the open access journal BMJ Nutrition Prevention & Health.

19 Dec 2023

From diabetes drug to anti-inflammation powerhouse: The unexpected evolution of GLP-1

Research pioneer Dr. Daniel Drucker has much to be proud of, as the GLP-1-based diabetes drugs hailing from his early research are named 2023 breakthrough of the year by the Science Magazine.

18 Dec 2023

Semaglutide News and Research

Latest Semaglutide News and Research

An Arm and a Leg: Wait, is Insulin cheaper now?

Bariatric surgery outperforms medical management in long-term diabetes control

Underutilized obesity treatments could transform patient health

Lactocore Group leverages milk peptides to combat inflammaging

AMG 133 (maridebart cafraglutide) weight loss drug shows promise in early trial

New weight loss drug may be an effective strategy for preventing or treating high blood pressure

Over 80% of semaglutide users achieve significant weight loss after 12 months, study finds

What does the future hold for obesity medication development?

Breakthrough obesity treatments on the horizon, rivaling surgery's success

SGLT2 inhibitors linked to lower risk of kidney stones in patients with type 2 diabetes

Fermented foods linked to mental health benefits through gut-brain connection

Study links GLP1 agonists to reduced risk of severe liver disease in diabetic patients

Dietary factors influencing GLP-1 secretion: a new perspective in diabetes and obesity treatment

Diabetes drugs may help curb alcohol dependence

GLP-1R agonist liraglutide rapidly improves insulin sensitivity in pre-diabetics, independent of weight loss

Combination therapy of dapagliflozin and semaglutide shows superior efficacy in type 2 diabetes management

MIT engineers develop 'vibing belly' pill to control appetite and curb obesity

MHRA provides 5 festive top tips for people taking medicines or using medical devices

Diabetes drug may help women avoid weight gain after quitting smoking

From diabetes drug to anti-inflammation powerhouse: The unexpected evolution of GLP-1

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Semaglutide News and Research

Latest Semaglutide News and Research

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Newsletters you may be interested in